Literature DB >> 22802462

Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein.

Carlos L J Vrins1, Roelof Ottenhoff2, Karin van den Oever3, Dirk R de Waart3, J Kar Kruyt4, Ying Zhao4, Theo J C van Berkel4, Louis M Havekes5, Johannes M Aerts2, Miranda van Eck4, Patrick C N Rensen5, Albert K Groen6.   

Abstract

Transintestinal cholesterol efflux (TICE) provides an attractive target to increase body cholesterol excretion. At present, the cholesterol donor responsible for direct delivery of plasma cholesterol to the intestine is unknown. In this study, we investigated the role of HDL in TICE. ATP-binding cassette protein A1 deficient (Abca1(-/-)) mice that lack HDL and wild-type (WT) mice were intravenously injected with chylomicron-like emulsion particles that contained radiolabeled cholesterol that is liberated in the liver and partly reenters the circulation. Both groups secreted radiolabeled cholesterol from plasma into intestinal lumen and TICE was unaltered between the two mouse models. To further investigate the role of HDL, we injected HDL with radiolabeled cholesterol in WT mice and Abca1(-/-)×Sr-b1(-/-) mice that lack HDL and are also unable to clear HDL via the liver. The intestines of both mice were unable to take up and secrete radiolabeled cholesterol from HDL via TICE. Although a generally accepted major player in the hepatobiliary route-based cholesterol excretion, HDL plays no significant role in TICE in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22802462      PMCID: PMC3435535          DOI: 10.1194/jlr.M022194

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  33 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Biliary sterol secretion is not required for macrophage reverse cholesterol transport.

Authors:  Ryan E Temel; Janet K Sawyer; Liqing Yu; Caleb Lord; Chiara Degirolamo; Allison McDaniel; Stephanie Marshall; Nanping Wang; Ramesh Shah; Lawrence L Rudel; J Mark Brown
Journal:  Cell Metab       Date:  2010-07-07       Impact factor: 27.287

3.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

4.  Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss.

Authors:  J Mark Brown; Thomas A Bell; Heather M Alger; Janet K Sawyer; Thomas L Smith; Kathryn Kelley; Ramesh Shah; Martha D Wilson; Matthew A Davis; Richard G Lee; Mark J Graham; Rosanne M Crooke; Lawrence L Rudel
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

5.  Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo.

Authors:  Miranda Van Eck; Menno Hoekstra; Ruud Out; I Sophie T Bos; J Kar Kruijt; Reeni B Hildebrand; Theo J C Van Berkel
Journal:  J Lipid Res       Date:  2007-10-22       Impact factor: 5.922

Review 6.  Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins.

Authors:  A R Tall
Journal:  J Intern Med       Date:  2008-03       Impact factor: 8.989

7.  Regulation of direct transintestinal cholesterol excretion in mice.

Authors:  Astrid E van der Velde; Carlos L J Vrins; Karin van den Oever; Ingar Seemann; Ronald P J Oude Elferink; Miranda van Eck; Folkert Kuipers; Albert K Groen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-29       Impact factor: 4.052

8.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.

Authors:  Daniel J Rader; Eric T Alexander; Ginny L Weibel; Jeffrey Billheimer; George H Rothblat
Journal:  J Lipid Res       Date:  2008-12-08       Impact factor: 5.922

9.  Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol.

Authors:  François Briand; Snehal U Naik; Ilia Fuki; John S Millar; Colin Macphee; Max Walker; Jeffrey Billheimer; George Rothblat; Daniel J Rader
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.438

10.  Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol.

Authors:  Jelske N van der Veen; Theo H van Dijk; Carlos L J Vrins; Hester van Meer; Rick Havinga; Klaas Bijsterveld; Uwe J F Tietge; Albert K Groen; Folkert Kuipers
Journal:  J Biol Chem       Date:  2009-05-05       Impact factor: 5.157

View more
  21 in total

1.  Blackcurrant anthocyanins stimulated cholesterol transport via post-transcriptional induction of LDL receptor in Caco-2 cells.

Authors:  Bohkyung Kim; Minkyung Bae; Young-Ki Park; Hang Ma; Tao Yuan; Navindra P Seeram; Ji-Young Lee
Journal:  Eur J Nutr       Date:  2017-07-17       Impact factor: 5.614

Review 2.  A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion.

Authors:  Ryan E Temel; J Mark Brown
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

3.  Simultaneous Determination of Biliary and Intestinal Cholesterol Secretion Reveals That CETP (Cholesteryl Ester Transfer Protein) Alters Elimination Route in Mice.

Authors:  Jianing Li; Sonja S Pijut; Yuhuan Wang; Ailing Ji; Rupinder Kaur; Ryan E Temel; Deneys R van der Westhuyzen; Gregory A Graf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-29       Impact factor: 8.311

Review 4.  From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport.

Authors:  Alberto Dávalos; Carlos Fernández-Hernando
Journal:  Pharmacol Res       Date:  2013-02-19       Impact factor: 7.658

Review 5.  Intestinal nuclear receptors in HDL cholesterol metabolism.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  J Lipid Res       Date:  2014-07-28       Impact factor: 5.922

6.  Emerging pathways in the regulation of whole body cholesterol flux: therapeutic opportunities to target atherosclerosis?

Authors:  Rabban Mangat; Spencer D Proctor
Journal:  J Lipid Res       Date:  2014-03-26       Impact factor: 5.922

7.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

Review 8.  Transintestinal cholesterol excretion in health and disease.

Authors:  Damien Garçon; Jean-Matthieu Berger; Bertrand Cariou; Cédric Le May
Journal:  Curr Atheroscler Rep       Date:  2022-02-09       Impact factor: 5.113

9.  Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice.

Authors:  Arne Dikkers; Wijtske Annema; Jan Freark de Boer; Jahangir Iqbal; M Mahmood Hussain; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2014-02-07       Impact factor: 5.922

10.  Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in mice.

Authors:  Kanwardeep S Bura; Caleb Lord; Stephanie Marshall; Allison McDaniel; Gwyn Thomas; Manya Warrier; Jun Zhang; Matthew A Davis; Janet K Sawyer; Ramesh Shah; Martha D Wilson; Arne Dikkers; Uwe J F Tietge; Xavier Collet; Lawrence L Rudel; Ryan E Temel; J Mark Brown
Journal:  J Lipid Res       Date:  2013-04-05       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.